

## Herpes simplex viruses type 1 and 2 photoinactivated in the presence of methylene blue transform human and mouse cells *in vitro*

M. MICHŮTOVÁ<sup>1</sup>, V. MRÁZOVÁ<sup>2</sup>, M. KÚDELOVÁ<sup>3\*</sup>, M. SMOLINSKÁ<sup>1</sup>, M. ŠUPOLIKOVÁ<sup>1</sup>, M. VRBOVÁ<sup>1</sup>, F. GOLAIS<sup>1\*</sup>

<sup>1</sup>Department of Microbiology and Virology, Faculty of Natural Science, Comenius University in Bratislava, Ilkovičova 6, 842 15 Bratislava, Slovak Republic; <sup>2</sup>St Elizabeth Cancer Institute, Bratislava, Slovak Republic; <sup>3</sup>Department of Molecular Pathogenesis of Viruses, Institute of Virology, Biomedical Research Center Slovak Academy of Sciences, Bratislava, Slovak Republic

Received February 21, 2017; revised March 29, 2017; accepted June 26, 2017

**Summary.** – Three strains of herpes simplex virus, K17<sup>syn-</sup> and HSZP<sup>syn+</sup> of type 1 (HSV-1) and US<sup>syn-</sup> of type 2 (HSV-2), were photoinactivated in the presence of methylene blue and used to infect 3 cell lines, normal human lung tissue cells (MRC-5), mouse epithelial cells (NIH3T3), and human lung carcinoma cells (A549). The virus titer and phenotype of cells were evaluated to compare the characteristics of normal and carcinoma cells infected with non-syncytial (non-syn) and syncytial (syn) strains of herpes simplex viruses. We found that the cells of both normal cell lines infected with photoinactivated K17<sup>syn-</sup> and US<sup>syn-</sup> but not HSZP<sup>syn+</sup> acquired transformed phenotype accompanied by the presence of virus. Surprisingly, the infection with photoinactivated viruses K17<sup>syn-</sup> and US<sup>syn-</sup> but not HSZP<sup>syn+</sup> resulted in the suppression of the transformed phenotype of A549 cells. Using nested PCR, herpesviral DNA was identified in newly transformed cells and cells that lost the transformed phenotype. The effect of putative herpesvirus-related growth factors (HRGF) produced by cells infected with photoinactivated viruses was quantified and compared. Since methylene blue is currently used in phototherapy of herpetic lesions, these results raise the question of whether such therapy is risky to human health.

**Keywords:** herpes simplex viruses; photoinactivation of viruses; methylene blue; putative herpesvirus-related growth factors; transformed phenotype; phototherapy

### Introduction

At present, there is no direct evidence that human alphaherpesviruses herpes simplex virus type 1 (HSV-1) or 2 (HSV-2) may be oncogenic. Although some seroepidemiological and biological studies have pointed to the possible role of HSV-2 in the development of cervical cancer (Nahmias *et al.*, 1974; Goldberg and Gravell, 1976; Rapp and Red, 1976; Thankamani *et al.*, 1985), other attempts have failed to

support this idea (Vonka *et al.*, 1984; Lehtinen *et al.*, 2002). Both HSV-1 and HSV-2, however, are still considered to be in relationship to some cancers such as epithelial skin cancer (Ypiranga and de Morales, 2009), squamous cell carcinoma (Metgut *et al.*, 2012; Gupta and Metgud, 2013), oral cancer (Shillitoe and Silverman, 1979; Stele and Shillitoe, 1991), oropharyngeal cancer (Starr *et al.*, 2001), thyroid cancer (Stamatiou *et al.*, 2016), and prostate cancer (Thomas *et al.*, 2011, Yun *et al.*, 2016). Attempts to demonstrate the ability of human alphaherpesviruses to transform cells *in vivo* failed as their transforming potential is masked by extensive cytopathology and the death of infected cells. The elimination of cell death could be accomplished for example by UV irradiation. UV-irradiated HSV-1 and HSV-2 lost their ability to cause cytopathic effect (CPE) and foci of transformed cells appeared in the culture monolayer (Duff and Rapp,

\*Corresponding authors. Dr. F. Golais: E-mail: franz\_golais@yahoo.de; phone: +421-2-60296-487; Dr. M. Kúdelová: E-mail: virukude@savba.sk; phone: +421-2-59302-434.

**Abbreviations:** HRGF = putative herpesvirus-related growth factors; HSV-1,-2 = herpes simplex virus type 1 and 2; MB = methylene blue; MHV-68 = murine gammaherpesvirus 68; NR = neutral red

1971; Rapp and Duff, 1973). Recently, similar results were obtained by Mrázová *et al.* (2015) with UV-irradiated murine gammaherpesvirus 68 (MHV-68).

Another approach to eliminate the lytic activity of viruses is photodynamic inactivation, when a virus is treated with photosensitizer such as neutral red (NR) or methylene blue (MB) and exposed to visible light. This treatment results in the destruction of virus infectivity (Yen and Simon, 1978; Schnipper *et al.*, 1980; Bodylak *et al.*, 1983; Costa, 2012). Studies employing the photoinactivation of HSV-1 and HSV-2 in the presence of NR have shown that under conditions, in which virus infectivity is destroyed, the photoinactivated virus can morphologically transform the cells *in vitro*, similar to UV-irradiated virus (Li *et al.*, 1975, Kucera *et al.*, 1977; Rapp and Kemeny, 1977). All cells transformed by HSV-1 and HSV-2 shared similar properties. They synthesized HSV-specific antigens detected by immunofluorescence, contained virus DNA, were resistant to superinfection with homologous transforming virus, and produced tumors in weanling animals after subcutaneous inoculation. Tumor-bearing animals produced neutralizing antibodies against transforming virus (Rapp and Duff, 1973; Rapp and Reed, 1976; Kucera *et al.*, 1977). Similar results were obtained in cells transformed by UV-inactivated MHV-68. Virus DNA and virus antigen could be detected by PCR and immunofluorescence methods; furthermore, the disappearance of actin bundles was observed, indicating that transformed cells might be oncogenic (Mrázová *et al.*, 2015).

In the 1990s, a novel class of compounds resembling growth factors, which cannot be related to any hitherto known cellular products, was found produced by herpesviruses and characterized. These putative HRGF have the ability to transform normal non-transformed cells and to suppress the transformed phenotype when added to transformed cells. Both activities of putative growth factors could be neutralized not only by antisera to the corresponding virus, but also by some monoclonal antibodies directed against viral gB glycoproteins (Golais *et al.*, 1988, 1992a,b; Konvalina *et al.*, 2002; Šupolíková *et al.*, 2015). It has been also found that non-syncytial but not syncytial strains of HSV-1 were able to produce these compounds during infection of cells (Golais *et al.*, 1992a,b). To take a position on this, we included into the study HSZP strain of HSV-1, suggested to be associated with the absence of HRGF in some cells. HSZP is a non-pathogenic syncytial strain of HSV-1 forming large polykaryocytes in infected cell cultures due to a syn<sup>3</sup> mutation in the C-terminal endodomain of glycoprotein B (Rajčáni *et al.*, 1996,1999; Kúdelová *et al.*, 1998). Several important *in vitro* and molecular studies have shown abolished shutoff function of the HSZP virus due to at least four out of six specific mutations seen in vhs polypeptide encoded by the UL41 gene (Matis and Kúdelová, 2001). *In vivo* studies have shown that HSZP is

poorly reactivable and shows limited neural spread in mice (Kúdelová *et al.*, 1996).

As already mentioned, photoinactivated herpesviruses may transform cells *in vitro*, thus indicating that they might be oncogenic *in vivo*. A human clinical therapeutic procedure based on photodynamic inactivation has been developed. This treatment consists of applying a photosensitizing dye to herpetic lesions and then exposing them to visible light. Taking into account previous data, this procedure can represent a potential cancer risk (Bockstahler *et al.*, 1979; Rapp and Li, 1982). NR was one of the first, although not very effective, photosensitizers used for treatment of herpetic lesions (Myers *et al.*, 1975, 1976; Roome *et al.*, 1975). However, satisfactory results have been obtained using MB (Chang *et al.*, 1975; Tardivo *et al.*, 2005, 2012; Marotti *et al.*, 2009, 2010; Sperandio *et al.*, 2009; Ramalho *et al.*, 2015). No transforming ability of any strain of HSV-1 or HSV-2 photoinactivated in the presence of MB has been demonstrated as yet.

The aim of this study was to evaluate the impact of *in vitro* infection with photoinactivated HSV-1 and HSV-2 of normal non-transformed and transformed cells, respectively, contributing to the clarification of the possible health hazard of the aforementioned treatment of herpetic lesions. Some issues of HSV-1- and HSV-2-associated putative growth factors were also addressed.

## Materials and Methods

**Viruses.** The HSV-1 K17 strain was obtained from the MRC-University of Glasgow Centre for Virus Research, Glasgow (Scotland, UK). This strain has non-syncytial (in this study designed as HSV-1 K17<sup>syn-</sup>) plaque morphology (Shubak-Sharp, 1973). The HSV-1 HSZP strain and the HSV-2 US strain were obtained from the collection of the Department of Molecular Pathogenesis of Viruses, Institute of Virology, Biomedical Research Center, Bratislava (Slovakia). HSZP is a non-pathogenic syncytial (in this study designed as HSV-1 HSZP<sup>syn+</sup>) strain of HSV-1 forming large polykaryocytes in infected cells. HSV-2 US has non-syncytial (in this study designed as HSV-2 US<sup>syn-</sup>) plaque morphology.

**Cells.** The following cells were used: BHK-21 cells (ATCC CCL-10) derived from the kidneys of 1-day-old hamsters (Stoker and MacPherson, 1964); MRC-5 (ATCC CCL-171), a human diploid cell culture established from the normal lung tissue of a 14-week-old male fetus (Jacobs *et al.*, 1970); NIH3T3 cells, mouse fibroblasts obtained from Swiss albino mouse embryo tissue (Todaro and Green, 1963); and A549 cells (ATCC CRM-CCL-185), a human lung carcinoma cell line originating from an explant culture of carcinomatous lung tissue from a 58-year-old Caucasian male (Giard *et al.*, 1973). The cells were cultivated in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 7% fetal bovine serum (FBS), 1% L-glutamine, and 1% Penicillin/Streptomycin/

Amphotericin B (PSA) and incubated at 37°C in a humidified 5% CO<sub>2</sub> atmosphere.

**Photodynamic inactivation.** Methylene blue (Loba Feinchemie GmbH, Fischamend, Austria) diluted in phosphate-buffered saline was added to 1 ml of virus suspension of HSV-1 K17<sup>syn-</sup>, HSV-1 HSZP<sup>syn+</sup>, and HSV-2 US<sup>syn-</sup> containing 1 x 10<sup>6</sup> PFU in 6 cm plastic Petri dishes to a final concentration of 10<sup>3</sup> mmol/l. The virus suspension was then exposed to light-emitting diodes (LED) at a distance of 5 cm at 37°C. A monochromatic LED red light system (homemade device,  $\lambda_{\max}$  = 650 nm, 16.7 Wm<sup>-2</sup>) was used for the experiments. The emission spectrum of the light system was measured with an optical fiber high resolution Red Tide USB-650 fiber optic spectrometer (Ocean Optics, Dunedin, FL, USA). Virus suspension samples taken at intervals 0, 30, 60, 90, and 120 s after exposure to visible light were used to infect BHK-21 cells and the virus titer of each individual sample was evaluated. Appropriate photoinactivated samples of viruses were diluted 10 and 100 times and then used to infect triplicates of monolayers of MRC-5, NIH3T3, and A549 cells grown in 24-well plates. Infected cells were observed daily for the appearance of morphological changes. Virus suspensions added to the cells containing the same MB concentration but not exposed to visible light (kept in the dark) and the cells infected with the same dose of non-photoinactivated virus served as negative and positive controls, respectively.

**Titration of viruses by plaque assay.** Ten-fold dilutions of virus samples in the amount of 0.1 ml were inoculated onto monolayers of BHK-21 cells in the 24-well plates in triplicate. After an incubation period of 60 min to allow the virus to adsorb to the cells, the monolayers were overlaid with a nutrient medium containing 0.5% methylcellulose that prevented virus release from the infected cells so that only cell-to-cell spread occurred. After 72 h, the medium containing methylcellulose was removed and the cells were fixed with 4% formalin and stained with carbolfuchsin. The plaques were counted and the virus titers were expressed as PFU/ml. Data were expressed as mean  $\pm$  SD obtained from triplicates.

**Morphological and cytological examination of cells.** The cells cultivated in 6-cm plastic Petri dishes were fixed with 50% methanol for 10 min, then 10 min with 100% methanol, and stained using the Giemsa-Romanowski method.

**Titration of HRGF.** To evaluate the transforming activity of HRGF, 10-fold dilutions (from 10<sup>0</sup> to 10<sup>8</sup>) of media from cells infected with photoinactivated viruses were added to NIH3T3 or MRC-5 cells grown in 96-well microplates in quadruplicates. The same media samples were added to carcinoma A549 cells to evaluate the transformed phenotype-suppressing activity of HRGF. The limiting dilution of the sample that induced the corresponding activity in 50% of the cells was considered as 1 HRGF unit. The titer of HRGF (as U/ml) of each sample was calculated taking into account the dilution of the media used. Data were expressed as mean  $\pm$  SD obtained from quadruplicates.

**Polymerase chain reaction.** To detect each strain of HSV-1 or HSV-2 in the examined samples, we used the nested PCR assay targeting the gp061 gene common sequence of both types (in the

virus genome from 93,113 to 94,579 nt) encoding the binding protein (GeneBank NC\_001806.2). DNA of HSV-1 BAC, HSV-1 K17, and HSV-1 HSZP were purified as previously described and used as a positive control (Kúdelová *et al.*, 1996). DNA from uninfected cells and the PCR mixture without the template were used as negative controls. The sequences of the outer and nested PCR primers (5'-GTGGTTCGTCGACGATTGCAGCAT-3' and 5'-GGGAGT GACCCGCGTGGTCTGA-3'; 5'-CGACGCGTACCGGTC CGATG-3' and 5'-TGGTGCACGAACAGCGTGGTG-3') amplified 377- and 311-bp-long products, respectively. The primers were synthesized by Microsynth (Balgach, Switzerland). The PCR mixture contained 50 mmol/l KCl, 10 mmol/l Tris-HCl (pH 8.5), 0.1% Triton X-100, 1.5 mmol/l MgCl<sub>2</sub>, 0.3 mmol/l nucleotides, 0.3 mmol of each primer, 1 U of GoTaq polymerase (Promega, Madison, WI, USA), and the template. The PCR procedure was performed in a 25- $\mu$ l total volume with 40 cycles of 94°C for 30 s, 57°C for 30 s, and 72°C for 45 s, followed by an extension in a thermal Labcycler (SensoQuest, Göttingen, Germany) at 72°C for 5 min. For the second (nested) round, 1  $\mu$ l of the first-round PCR was used as a template under identical conditions, except 35 cycles were used.

## Results and Discussion

To evaluate the effect of photodynamic inactivation on HSV-1 K17<sup>syn-</sup>, HSV-1 HSZP<sup>syn+</sup>, and HSV-2 US<sup>syn-</sup>, we exposed virus samples of titer approximately 1 x 10<sup>6</sup> PFU/ml to visible light at various time intervals (from 30 to 120 s) in the presence of MB. Photoinactivated viruses were then diluted 10 and 100 times and used to infect 24-h-old monolayers of NIH-3T3, MRC-5, and A549 cells. Untreated viruses diluted in the same manner served as negative controls. After 3 days of culture, the titer in the culture media of photoinactivated viruses was evaluated and compared to the controls. We found that the titer of all photoinactivated viruses continuously decreased with increasing light exposure time. As shown in Fig. 1, exposure of 30 s to visible light in the presence of MB caused about 30% decrease of infectivity in all viruses, while the strongest effect on HSV-2 US<sup>syn-</sup> could be observed. Furthermore, the infectivity of all viruses was around 50% after 120 s of exposure.

Following 7 days of culture of NIH3T3 and MRC-5 infected with photoinactivated HSV-1 K17<sup>syn-</sup>, HSV-1 HSZP<sup>syn+</sup>, or HSV-2 US<sup>syn-</sup>, most of the cells of both cell lines showed incomplete CPE (about 70–90%), whereas cells infected with untreated viruses were destroyed by a total CPE within 3 days. After 7 days of culture, a relatively small portion of cells of both cell lines infected with any of the photoinactivated HSV-1 K17<sup>syn-</sup> and HSV-2 US<sup>syn-</sup> remained undestroyed by virus infection but acquired altered morphology resembling transformation with a multilayered "criss-cross" pattern of growth. Moreover, cells could be subsequently passaged without the loss of transformed phenotype. We found that NIH3T3






Fig. 1

Reduction of infectivity of HSV-1 K17<sup>syn-</sup>, HSV-1 HSZP<sup>syn+</sup>, and HSV-2 US<sup>syn-</sup> exposed to visible light for 30–120 s. Untreated viruses served as negative controls. Data are expressed as mean  $\pm$  SD obtained from triplicates.




Fig. 2

Changes in NIH3T3 cells phenotype caused by infection with photoinactivated HSV-1 K17<sup>syn-</sup> (a and b) and HSV-1 HSZP<sup>syn+</sup> (c) (a) and (b) cells after the fifth and tenth passage; (c) cells after the fifth passage; (d) uninfected cells (negative control); magnification 50x.

cells at fifth and tenth passage still displayed the transformed phenotype caused by the photoinactivated HSV-1 K17<sup>syn-</sup> (Fig. 2a,b) and HSV-2 US<sup>syn-</sup> (data not shown). Similarly,




Fig. 3

Changes in MRC-5 cells phenotype caused by infection with photoinactivated HSV-2 US<sup>syn-</sup>. (a) cells after the fifth passage; (b) uninfected cells (negative control). Magnification 50x.

MRC-5 cells displayed the transformed phenotype caused by the photoinactivated HSV-1 K17<sup>syn-</sup> (data not shown) and HSV-2 US<sup>syn-</sup> (Fig. 3a). We found that both non-syn herpes simplex viruses of both types used in this study induced stable transformed phenotype in MRC-5 as well as NIH3T3 cells. On the other hand, the infection with photoinactivated syncytial HSV-1 HSZP<sup>syn+</sup> failed to induce such transformation and the phenotype of NIH3T3 (Fig. 2c) and MRC-5 cells (data not shown) remained the same as that of the cells infected with untreated virus or uninfected cells (Figs. 2d and 3b).

In the following experiments, we investigated virus presence in both of cell lines transformed by photoinactivated




Fig. 4

Changes in carcinoma cells A549 phenotype caused by infection with photoinactivated HSV-1 K17<sup>syn-</sup> (a) and HSV-1 HSZP<sup>syn+</sup> (b) (a) and (b) cells after the fifth and sixth passage; (c) uninfected cells (negative control). Magnification 50x.

herpes simplex viruses by nested PCR method. Despite of the different effect observed on cells after infection with photoinactivated non-syn (HSV-1 K17<sup>syn-</sup> and HSV-2 US<sup>syn-</sup>) and

syn (HSV-1 HSZP<sup>syn+</sup>) strains, we identified the presence of viral DNA in MRC-5 cells (Fig. 5a) and NIH3T3 cells (data not shown), respectively.

Next, in experiments on carcinoma A549 cells infected with photoinactivated viruses, we observed an opposite effect found for normal cells: a change of transformed phenotype into phenotype resembling the phenotype of normal non-transformed cells. The cells infected with HSV-1 K17<sup>syn-</sup> (Fig. 4a) and HSV-2 US<sup>syn-</sup> (data not shown) retained a normal, non-transformed phenotype after at least 5 following passages. On the other hand, photoinactivated HSV-1 HSZP<sup>syn+</sup>, unlike non-syn herpes simplex viruses, failed to induce such a change in the transformed phenotype of A549 cells, which remained unchanged after at least 6 following passages (Fig. 4b). The investigation by molecular methods of A549 cell lines, which after infection with photoinactivated viruses lost transformed phenotype or remained transformed, has shown the presence of DNA of HSV-1 K17<sup>syn-</sup> and HSV-1 HSZP<sup>syn+</sup> in relevant cells (Fig. 5b)

The fact that photoinactivated syncytial HSV-1 HSZP<sup>syn+</sup> did not induce the morphological changes either in non-transformed NIH3T3 and MRC-5 cells or transformed A549 cells suggest that cells of all these cell lines infected with this virus did not produce compounds resembling growth factors, HRGF, previously shown in cells transformed by some herpesviruses. We found that photoinactivated HSZP is not capable of transforming non-transformed cells and suppressing the transformed phenotype of transformed cells, what is consistent with previous finding that syncytial strains of HSV-1 failed to produce HRGF (Golais *et al.*, 1992a,b; Konvalina *et al.*, 2002). However, this finding is very interesting and needs further studies.

In this study, we demonstrated the acquisition of the transformed phenotype by NIH3T3 and MRC-5 cells as well as the change of the transformed phenotype of A549 cells




Fig. 5

PCR detection of HSV-1 viruses in MRC-5 cells transformed via infection with photoinactivated virus strain K17<sup>syn-</sup> or HSZP<sup>syn+</sup> (a) and A549 cells that lose transformed phenotype after infection with inactivated virus strain K17<sup>syn-</sup> or HSZP<sup>syn+</sup> (b)

(a) Lanes 1: 100 bp Plus Ladder (Fermentas); 2 and 3: nested PCR with HSV-1 BAC DNA and 1-step PCR with nested primers and HSV-1 BAC DNA (positive controls); 4: nested PCR without template (negative control); 5: uninfected cells (negative control); 6 and 7: MRC-5 cells infected with photoinactivated K17<sup>syn-</sup> and HSZP<sup>syn+</sup> (eighth passage). (b) Lanes 1: 100 bp Plus Ladder (Fermentas); 2–3 and 4–5: A549 cells infected with photoinactivated HSZP<sup>syn+</sup> and K17<sup>syn-</sup> diluted 20 times (lanes 2 and 4) and 100 times (lanes 3 and 5); 6: uninfected cells (negative control); 7 and 8: nested PCR with DNA of HSZP and K17 (positive controls); 9 and 10: 1-step PCR with nested primers and DNA of HSZP and K17 (positive controls); 11 and 12: nested PCR without template and 1-step PCR with nested primers without template (negative controls).




Fig. 6

Titration of putative HRGF produced by MRC-5, NIH3T3, and A549 cells infected with photoactivated HSV-1 K17<sup>syn-</sup>, HSV-1 HSZP<sup>syn+</sup>, and HSV-2 US<sup>syn-</sup> by limiting dilution assay on BHK-21 cells

Data expressed as mean  $\pm$  SD obtained from quadruplicates ranged from 0.004 to 0.006.

towards the normal one following infection with photoactivated non-syncytial herpes simplex viruses HSV-1 K17<sup>syn-</sup> and HSV-2 US<sup>syn-</sup>. Similar changes of phenotype in normal and transformed cells were recently described for NIH3T3 and HeLa cells infected with UV-irradiated MHV-68 and suggested to be related to putative growth factor MHGF-68 (Mrázová *et al.*, 2015; Šupolíková *et al.* 2015).

Finally, we compared the production of virus-related growth factors by all cell phenotypes involved. As described in Material and Methods, we quantified the effect of HRGF induced in NIH3T3, MRC-5, and A549 cells by infection with all 3 photoactivated viruses. Data obtained confirmed that HRGF displayed the strongest effect on the phenotype of NIH3T3 cells infected with photoactivated non-syncytial strains of HSV-1 and HSV-2. However, no effect of photoactivated HSV-1 HSZP<sup>syn+</sup> on the phenotype of any cell line was observed (Fig. 6).

Results suggest that the non-syncytial phenotype of herpes simplex virus strains is required for the production of HRGF, which plays an important role in the change of the phenotype of virus-infected cells. It is interesting that the effect of HRGF induced by infection of normal mouse NIH3T3 cells, but also human carcinoma A549 cells, with non-syncytial HSV-2 is stronger than that caused by non-syncytial HSV-1. This work represents the first study on the absence of effects of photoactivated HSV-1 HSZP<sup>syn+</sup> on normal as well as transformed cells what is most likely related to the absence of putative growth factors.

As follows from this study, the infection of non-transformed cells with HSV-1 or HSV-2 photoactivated in the presence of MB may result in their transformation, which might render this method hazardous. The aim of this work was not to doubt the success of the phototherapy on herpetic lesions. The data gained here pose the question of whether the virus is capable of transforming the cells *in vivo* and could also be oncogenic in an organism. Nevertheless, the development of modern photodynamic therapy procedures as well as the use of suitable photosensitizers could minimize or remove the possible side effects of this treatment, as suggested by Wainwright (2003).

**Acknowledgements.** This work was supported by grant #APVV-0621-12 of the Slovak Research and Development Agency and grant VEGA#2/0087/17. The authors appreciate the HSV-1 BAC kindly provided by Prof. Ulrich H. Koszinowski.

## References

- Bockstahler LE, Coohill TP, Hellman KB, Lytle CD, Roberts JE (1979): Photodynamic therapy for herpes simplex. A critical Review. *Pharmacol. Ther.* 4, 473–499. [https://doi.org/10.1016/0163-7258\(79\)90144-X](https://doi.org/10.1016/0163-7258(79)90144-X)
- Bodilyak JA, Scherba G, Gustafson DP (1983): Photodynamic inactivation of pseudorabiesvirus with methylene blue dye, light and electricity. *J. Clin. Microbiol.* 17, 374–376.
- Costa L, Faustino MAF, Neves MGPMS, Cunha A, Almeida A (2012): Photodynamic inactivation of mammalian vi-



- ruses and bacteriophages. *Viruses* 4, 1034–1074. <https://doi.org/10.3390/v4071034>
- Duff R, Rapp F (1971): Properties of hamster embryo fibroblasts transformed in vitro after exposure to ultraviolet-irradiated herpes simplex virus type 2. *J. Virol.* 8, 469–477.
- Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP (1973): In vitro cultivation of human tumors: establishment of cell lines derived from series of solid tumors. *J. Natl. Canc. Inst.* 51, 1417–1423. <https://doi.org/10.1093/jnci/51.5.1417>
- Golais F, Košťál M, Csabayová M, Leško J (1992b): The glycoprotein B gene and its syn3 locus of herpes simplex virus type 1 are involved in the synthesis of virus-associated growth factor (HSGF-1). *Acta Virol.* 36, 516–523.
- Golais F, Sabó A, Bačková D (1988): Transforming activity of crude extract of pseudorabiesvirus transformed cells. *Acta Virol.* 32, 83–85.
- Golais F, Csabayová M, Leško J, Bystrická M, Sabó A (1992a): Herpes simplex virus type 2 and pseudorabies virus associated growth factors and their role in the latency in vitro. *Acta Virol.* 36, 505–515.
- Goldberg RJ, Gravell M (1976): A search for herpes simplex virus type 2 markers in cervical carcinoma. *Cancer Res.* 36, 795–799.
- Gupta K, Metgud R (2013): Evidence suggesting involvement of viruses in oral squamous cell carcinoma. *Pathol. Res. Internat.* 2013, e17. <https://doi.org/10.1155/2013/642496>
- Chang TW, Fumara N, Weinstein L (1975): Genital herpes: Treatment with methylene blue and light exposure. *Int. J. Dermatol.* 14, 69–71. <https://doi.org/10.1111/j.1365-4362.1975.tb00084.x>
- Jacobs JP, Jones CM, Baille JP (1970): Characteristics of human diploid cells designated MRC5. *Nature* 227, 168–170. <https://doi.org/10.1038/227168a0>
- Konvalina I, Gašperík J, Golais F (2002): A novel class of growth factors related to herpesviruses. *Acta vet. Brno* 71, 29–36. <https://doi.org/10.2754/avb200271010029>
- Kucera LS, Gudson JP, Edwards I, Herbst G (1977): Oncogenic transformation of rat embryo fibroblasts with photoactivated herpes simplex virus: Rapid in vitro cloning of transformed cells. *J. Gen. Virol.* 35, 473–485. <https://doi.org/10.1099/0022-1317-35-3-473>
- Kúdelová M, Dragúň M, Košovský J, Matis J, Rajčáni J (1996): Determination of the target sequence of poorly reactivable strain HSZP of Herpes simplex virus type 1 by polymerase chain reaction. *Acta Virol.* 40, 15–21.
- Kúdelová M, Vojvodová A, Rajčáni J (1998): The syn strains HSZP and ANGpath of herpes simplex virus type 1 do not show mutations in the regions of UL 53 gene relevant to syncytium formation. *Acta Virol.* 42, 41–45.
- Lehtinen M, Koskela P, Jellum E *et al.* (2002): Herpes simplex virus and risk of cervical cancer: A longitudinal, nested case-control study in the nordic countries. *Am. J. Epidemiol.* 156, 687–692. <https://doi.org/10.1093/aje/kwf098>
- Li JL, Jerkoffsky MA, Rapp F (1975): Demonstration of oncogenic potential of mammalian cells transformed by DNA containing viruses following photodynamic inactivation. *Int. J. Cancer.* 15, 190–202. <https://doi.org/10.1002/ijc.2910150204>
- Marotti J, Aranha ACC, De Paula Eduardo C, Ribeiro MS (2009): Photodynamic therapy can be effective as a treatment for herpes simplex labialis. *Photomed. Laser Surg.* 27, 357–363. <https://doi.org/10.1089/pho.2008.2268>
- Marotti J, Sperandio FF, Fregnani ER, Aranha ACC, Moreira de Freitas P, Eduardo CdeP (2010): High-intensity laser and photodynamic therapy as a treatment for recurrent herpes labialis. *Photomed. Laser Surg.* 28, 439–444. <https://doi.org/10.1089/pho.2009.2522>
- Matis J, Kúdelová M (2001): Early shutoff of host protein synthesis in Herpes simplex virus 1 /HSV1/ infected cells. *Acta Virol.* 45, 269–277.
- Metgud R, Astekar M, Verma M, Sharma A (2012): Role of viruses in oral squamous cell carcinoma. *Oncol. Rev.* 6, e21. <https://doi.org/10.4081/oncol.2012.e21>
- Mrázová V, Betáková T, Kúdelová M, Šupolíková M, Lachová V, Lapuníková B, Golais F (2015): Murine gammaherpesvirus (MHV-68) transforms cultured cells in vitro. *Intervirology* 58, 69–72. <https://doi.org/10.1159/000370071>
- Myers MG, Oxman MN, Clark JE, Arndt KA (1975): Failure of neutral-red photodynamic inactivation in recurrent herpes simplex virus infections. *New Engl. J. Med.* 293, 945–949. <https://doi.org/10.1056/NEJM197511062931901>
- Myers MG, Oxman MN, Clark JE, Arndt KA (1976): Photodynamic inactivation in recurrent infection with herpes simplex virus. *J. Infect. Dis.* 133, 145–150. [https://doi.org/10.1093/infdis/133.Supplement\\_2.A145](https://doi.org/10.1093/infdis/133.Supplement_2.A145)
- Nahmias AJ, Naub ZM, Josey WE (1974): Epidemiological studies relating genital herpetic infection to cervical carcinoma. *Cancer Res.* 34, 1111–1117.
- Rajčáni J, Vojvodová A, Matis J, Kúdelová M, Dragúňová J, Krivjanská M, Zelník V (1996): The syn3 HSZP of Herpes simplex virus type 1 (HSV-1) is not pathogenic for mice and shows limited neural spread. *Virus Res.* 43, 33–44. [https://doi.org/10.1016/0168-1702\(96\)01318-4](https://doi.org/10.1016/0168-1702(96)01318-4)
- Rajčáni J, Kúdelová M, Oravcová I, Vojvodová A, Košovský J, Matis J (1999): Characterization of strain HSZP of herpes simplex virus type 1 (HSV-1). *Folia Microbiol.* 44, 713–719. <https://doi.org/10.1007/BF02825668>
- Ramalho KM, Rocha RG, Aranha ACC, Cunha SRB, Simoes A, Campos L, Eduardo CP (2015): Treatment of herpes simplex labialis in macule and vesicle phases with photodynamic therapy. Report of two cases. *Photodiagn. Photodyn.* 12, 321–323. <https://doi.org/10.1016/j.pdpdt.2015.02.005>
- Rapp F, Duff R (1973): Transformation of hamster embryo fibroblasts by herpes simplex virus type 1 and type 2. *Cancer Res.* 33, 1527–1534.
- Rapp F, Kemeny BA (1977): Oncogenic potential of herpes simplex virus in mammalian cells following photodynamic inactivation. *Photochem. Photobiol.* 25, 335–337. <https://doi.org/10.1111/j.1751-1097.1977.tb07349.x>
- Rapp F, Li JLH (1982): Transforming activity of viruses after dye-light inactivation. *The Science of Photomedicine*, 571–594. [https://doi.org/10.1007/978-1-4684-8312-3\\_21](https://doi.org/10.1007/978-1-4684-8312-3_21)

- Rapp F, Reed C (1976): Experimental evidence for the oncogenic potential of herpes simplex virus. *Cancer Res.* 36, 800–806.
- Roome AP, Tinkler AE, Hilton AE, Montefiore DG, Waller D (1975): Neutral red with photoinactivation in the treatment of herpes genitalis. *Brit. J. Vener. Dis.* 51, 130–133. <https://doi.org/10.1136/sti.51.2.130>
- Shillitoe EJ, Silverman S (1979): Oral cancer and herpes simplex virus—a review. *Oral Surg. Oral Med. Oral Pathol.* 48, 216–224. [https://doi.org/10.1016/0030-4220\(79\)90006-9](https://doi.org/10.1016/0030-4220(79)90006-9)
- Schnipper LE, Lewin AH, Schwartz M, Crumpacker CS (1980): Mechanism of photodynamic inactivation of herpes simplex viruses: comparison between methylene blue, light, plus electricity and hematoporphyrin plus light. *J. Clin. Invest.* 65, 432–438. <https://doi.org/10.1172/JCI109686>
- Sperandio FF, Marotti J, Aranha ACC, Eduardo C de P (2009): Photodynamic therapy for the treatment of recurrent herpes labialis: Preliminary results. *Gen. Dent.* 57, 415–419.
- Stamatiou DP, Derdas SP, Zoras OI, Spandidos DA (2016): Herpes and polyoma viruses in thyroid cancer (Review). *Oncol. Letters* 11, 1635–1644.
- Starr JR, Daling JR, Dawn Fitzgibbons E, Madeleine MM, Ashley R, Galloway DA, Schwartz SM (2001): Serologic evidence of herpes simplex infection and oropharyngeal cancer risk. *Cancer Res.* 61, 8459–8464.
- Stele C, Shillitoe EJ (1991): Viruses and oral cancer. *Crit Rev Oral Biol M.* 2, 153–175. <https://doi.org/10.1177/10454411910020020201>
- Stoker M, MacPherson I (1964): Syrian hamster fibroblast cell line BHK21 and its derivatives. *Nature* 203, 1355–1357. <https://doi.org/10.1038/2031355a0>
- Subak-Sharpe JH (1973): The genetics of herpesviruses. *Cancer Res.* 33, 1385–1392.
- Šupolíková M, Vojs Staňová A, Kúdelová M, Marák J, Zelník V, Golais F (2015): Cells transformed by murine herpesvirus 68 (MHV-68) release compounds with transforming and transformed phenotype suppressing activity resembling growth factors. *Acta Virol.* 59, 418–422. [https://doi.org/10.4149/av\\_2015\\_04\\_418](https://doi.org/10.4149/av_2015_04_418)
- Tardivo JP, Del Giglio A, Santos de Oliveira C, Couto Junqueira H, Batista Tada A, Severino D, Terchiello R de F, Baptista MS (2005): Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications. *Photo-diagn. Photodyn.* 2, 175–191. [https://doi.org/10.1016/S1572-1000\(05\)00097-9](https://doi.org/10.1016/S1572-1000(05)00097-9)
- Tardivo JP, Wainwright M, Baptista MS (2012): Local clinical phototreatment of herpes infection in Sao Paulo. *Photo-diagn. Photodyn.* 9, 118–121. <https://doi.org/10.1016/j.pdpdt.2012.01.002>
- Thankamani V, Vasudevan DM, Kumari TV (1985): Detection of herpes simplex virus type 2 antigen(s) in biopsies from carcinoma of the uterine cervix. *J. Exp Pathol.* 2, 123–133.
- Thomas F, Elguero E, Brodeur J, Brodeur J, Le Golf J, Misse D (2011): Herpes simplex virus type 2 and cancer: A medical geography approach. *Infect. Genet. Evol.* 11, 1239–1242. <https://doi.org/10.1016/j.meegid.2011.04.009>
- Todaro GJ, Gren H (1963): Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. *J. Cell. Biol.* 17, 299–313. <https://doi.org/10.1083/jcb.17.2.299>
- Kumari TV, Vosundevan DM, Ankathil R, Ramani P, Vijayakumar Y (1987): Demonstration of HSV-1 antigen in patients with oral cancer by immunofluorescence and immunoperoxidase techniques. *J. Exp. Pathol.* 3, 75–86.
- Vonka V, Kanaka J, Hirsch I, Závadová H, Krčmář M, Suchánková A, Řezáčová D, Brouček J, Press M, Domorázková E, Svoboda B, Havránková A, Jelinek J (1984): Prospective studies on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type 2 antibody presence in serataken at enrollment. *Int. J. Cancer.* 33, 61–66. <https://doi.org/10.1002/ijc.2910330111>
- Wainwright M (2003): Local treatment of viral disease using photodynamic therapy. *Int. J. Antimicrob. Ag.* 21, 510–520. [https://doi.org/10.1016/S0924-8579\(03\)00035-9](https://doi.org/10.1016/S0924-8579(03)00035-9)
- Yen GSL, Simon EH (1978): Photosensitization of herpes simplex virus type 1 with neutral red. *J. Gen. Virol.* 41, 273–281. <https://doi.org/10.1099/0022-1317-41-2-273>
- Ypiranga S, de Moraes AM (2009): Prevalence of human herpes virus type 1 in epithelial skin cancer. *Ann. Bras. Dermatol.* 84, 137–142. <https://doi.org/10.1590/S0365-05962009000200006>
- Yun SJ, Jeong P, Kang HW, Shinn HK *et al.* (2016): Increased expression of herpes virus-encoded hsv1 miR-H18 and hsv2 miR-H9-58 in cancer containing prostate tissue compared to that in benign prostate hyperplasia tissue. *Int. Neurol. J.* 20, 122–130. <https://doi.org/10.5213/inj.1632552.276>